Abstract: The present disclosure provides isolated, engineered, non-naturally occurring CB1 binding proteins, including anti-CB1 antibodies or antigen-binding fragment thereof. The CB1 binding proteins find utility in the treatment and diagnosis of CB1 mediated conditions, diseases and disorders.
Type:
Grant
Filed:
March 16, 2021
Date of Patent:
September 5, 2023
Assignee:
Takeda Pharmaceutical Company Limited
Inventors:
Antara Banerjee, Andrea Fanjul, Robert J. Hoey, Kacey Sachen, Nikolai Suslov
Abstract: There is disclosed compositions and methods relating to or derived from anti-CD123 antibodies. More specifically, there is disclosed fully human antibodies that bind CD123, CD123-antibody binding fragments and derivatives of such antibodies, and CD123-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.
Abstract: This invention relates to the dual targeting of cell inhibiting agents to the cell surface receptors CD7 and CD33 in the treatment of hematological malignancy. In particular, the invention relates to cell inhibiting agents that bispecifically binds to CD33 and CD7 for use in the treatment of a CD7+CD33+ hematological malignancy. Such agents may comprise bispecific antibody drug conjugates.
Abstract: The disclosure relates to immune cells comprising a dual receptor system responsive to loss of heterozygosity in a target cell, and methods of making and using same. The first receptor comprises activator receptor specific to a HER2 antigen, and the second receptor comprises an inhibitory receptor specific to an antigen lost in cancer but not wild type cells, that inhibits activation of the immune cells by the first receptor.
Type:
Grant
Filed:
June 28, 2022
Date of Patent:
August 22, 2023
Assignee:
A2 Biotherapeutics, Inc.
Inventors:
Yuta Ando, Julyun Oh, Han Xu, Carl Alexander Kamb
Abstract: Provided herein are isolated antibodies that specifically bind anti-CD19 chimeric antigen receptors (CARs) derived from a 4G7 scFv. Also provided are methods of making and using these isolated antibodies.
Type:
Grant
Filed:
April 17, 2020
Date of Patent:
August 22, 2023
Assignee:
ALLOGENE THERAPEUTICS, INC.
Inventors:
Thomas Charles Pertel, Barbra Johnson Sasu, Tao Sai
Abstract: The present invention relates to: a novel antibody or an antigen-binding fragment thereof for use in the treatment of cancer by targeting B cell malignancies; a chimeric antigen receptor comprising the same; and uses thereof. The antibody of the present invention is an antibody specifically binding to CD19 highly expressed in cancer cells (particularly, blood cancer) and has very low homology compared to the CDR sequences of conventional CD19 target antibodies, and thus the sequence thereof is unique. In addition, cells expressing a chimeric antigen receptor comprising an anti-CD19 antibody or antigen-binding fragment of the present invention induce immune cell activity in response to a positive cell line expressing CD19, and thus can be usefully used as a therapeutic agent for CAR-immune cells.
Type:
Grant
Filed:
December 21, 2018
Date of Patent:
July 25, 2023
Assignee:
ABCLON INC.
Inventors:
Jong Seo Lee, Kyu Tae Kim, Bong Kook Ko, Ki Hyun Kim
Abstract: Provided herein are chimeric transmembrane proteins and proteins, nucleic acids encoding these chimeric transmembrane proteins or proteins, and mammalian cells containing these nucleic acids, and methods of making and using these mammalian cells.
Type:
Grant
Filed:
June 21, 2019
Date of Patent:
July 25, 2023
Assignee:
Kite Pharma, Inc.
Inventors:
Peter Emtage, Gabrielle Romain, Rosa Vincent, Sarah Wyman
Abstract: Provided are anti-CD47 monoclonal antibodies (anti-CD47 mAbs) with distinct functional profiles as described herein, methods to generate anti-CD47 mAbs, and to methods of using these anti-CD47 mAbs as therapeutics for the prevention and treatment of solid and hematological cancers, ischemia-reperfusion injury, cardiovascular diseases, autoimmune diseases, inflammatory diseases or as diagnostics for determining the level of CD47 in tissue samples.
Type:
Grant
Filed:
December 4, 2019
Date of Patent:
July 4, 2023
Assignee:
Arch Oncology, Inc.
Inventors:
Pamela T. Manning, Robyn Puro, Juan C. Almagro, Robert W. Karr
Abstract: The present inventors discovered that problems of existing antibody pharmaceuticals can be solved by producing antigen-binding molecules that contain an antigen-binding domain whose antigen-binding activity varies depending on the concentration of a target tissue-specific compound. Use of antigen-binding molecules of the present invention enables various diseases that originate from a target tissue to be treated in a manner specific to the target tissue.
Abstract: Provided herein are antibodies and chimeric antigen receptor (CAR) cells comprising the antigen binding domains of these antibodies. Also provided are compositions comprising the same, vector or plasmid encoding the antibodies and CARs, and methods for producing the same, or using the same for detecting or treating cancer and kits for carrying out said methods.
Type:
Grant
Filed:
August 13, 2021
Date of Patent:
June 6, 2023
Assignee:
University of Southern California
Inventors:
Alan L. Epstein, Peisheng Hu, Long Zheng
Abstract: Disclosed herein are fusion proteins having a first domain that activates an antigen-presenting cell (APC) (e.g., a dendritic cell) by binding to an activation receptor of the APC, and a second domain that activates an immune effector cell (e.g., a T cell) by targeting a co-stimulatory signaling pathway of the immune effector cell, as well as polynucleotides that encode such fusion proteins. Disclosed herein are also genetically engineered immune effector cells expressing such fusion protein, methods of their production, and their uses in treatment of diseases such as cancers.
Abstract: The disclosure relates to polypeptides and pharmaceutical compositions comprising polypeptides that find use in the prevention or treatment of cancer, in particular gastric cancer, lung cancer, melanoma and bladder cancer. The disclosure also relates to methods of inducing a cytotoxic T cell response in a subject or treating cancer by administering pharmaceutical compositions comprising the peptides, and companion diagnostic methods of identifying subjects for treatment. The peptides comprise T cell epitopes that are immunogenic in a high percentage of patients.
Type:
Grant
Filed:
September 3, 2019
Date of Patent:
June 6, 2023
Assignee:
Treos Bio Limited
Inventors:
Julianna Lisziewicz, Levente Molnar, Eniko Toke, József Toth, Orsolya Lorincz, Zsolt Csiszovszki, Eszter Somogyi, Katalin Pantya, Mónika Megyesi
Abstract: The present application provides chimeric antibody-TCR constructs comprising an antigen-binding module that specifically binds to a target antigen and a T cell receptor module capable of recruiting at least one TCR-associated signaling molecule. Also provided are methods of making and using these constructs.
Type:
Grant
Filed:
April 24, 2018
Date of Patent:
March 28, 2023
Assignee:
EUREKA THERAPEUTICS, INC.
Inventors:
Lucas Horan, Yiyang Xu, Zhiyuan Yang, Hong Liu, Javier Morales, Lianxing Liu
Abstract: Provided herein are antigen-binding proteins (ABPs) that selectively bind to TIGIT and its isoforms and homologs, and compositions comprising the ABPs. Also provided are methods of using the ABPs, such as therapeutic and diagnostic methods.
Type:
Grant
Filed:
October 22, 2019
Date of Patent:
February 28, 2023
Assignee:
Potenza Therapeutics, Inc.
Inventors:
Daniel Hicklin, William Winston, Cynthia S. Dugan, Nels P. Nielson
Abstract: Described are antibodies that specifically bind to the Axl protein and inhibit the interaction between Axl and the Axl-ligand, Gas6. Also disclosed are methods for the production and use of the anti-Axl antibodies.
Type:
Grant
Filed:
December 19, 2018
Date of Patent:
February 21, 2023
Assignees:
BERGENBIO ASA, BERGEN TEKNOLOGIOVERFØRING AS
Inventors:
David Robert Micklem, Sergej Kiprijanov, James Bradley Lorens, Lavina Ahmed, Linn Hodneland Nilsson, Tone Sandal
Abstract: A method for assessing the risk of potential adverse effects for a human patient receiving is provided. The method comprises determining the total B count in the patient, and identifying a B cell number indicative of a patient at risk of potential adverse effects from the antibody. The method further provides a dosing schedule for administering the antibody to the patient identified as at risk of potential adverse effects. Also provided is a pharmaceutical package or kit comprising a first dose and a second dose, and optionally a third dose, the CD19×CD3 bispecific antibody as defined in the methods/dosage regimen of the disclosure.